Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy

    January 2022 in “ Yonsei Medical Journal ”
    Jae Yong Han, Yong Joon Kim, Eun Young Choi … Christopher Seungkyu Lee
    Studysummary This study found that oral spironolactone improved certain biomarkers in central serous chorioretinopathy patients, but recurrence, especially in older patients, was relatively common.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on eymj.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Oral Medications for Central Serous Chorioretinopathy: A Literature Review Eye · 2019
    2. Female Pattern Alopecia: Current Perspectives International Journal of Women's Health · 2013